- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03818451
Co-ultra PEALut Enhances Neuronal Recovery Following Moderate Traumatic Brain Injury (GLIA13)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Setting All patients affected by moderate TBI (Glasgow Coma Score 9-13) admitted to the neurosurgical department of the University Hospital of Messina, Italy, will be screened for recruitment.
Ethics The institutional review board (IRB) approved the study. Written consent will be obtained from each patient or the closest family member prior to the start of the study.
Study Design A randomized controlled single-blind study to assess the effects of co-ultraPEALut (Glialia®) administration in TBI patients will be carried out. The study is set to recruit at least 30 patients.
Recruited patients are randomly allocated to one of the two branches of the study: standard TBI treatment + Glialia® (Study Group) and standard TBI treatment (Control Group) in a 1:1 ratio using precompiled randomization tables.
General treatment
All patients will undergo standard treatments according to patterns of severity and in the light of distinct variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:
- Surgical evacuation of hemorrhagic masses and / or "debridement" of outbreaks brain contusion;
- Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Goals were a systolic blood pressure >90 mmHg and a cerebral perfusion pressure >60 mmHg. Prevention of secondary complications of critical illness included: preventive therapy of venous thromboembolism (VTE) using low molecular weight heparin (LMWH) and seizures using levetiracetam prophylactically for the first seven days after injury;
- Patient who underwent surgical treatment, received also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage.
Specific Treatment The investigations agent, the co-ultraPEALut, will be administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alfred Conti, MD, PhD; FEBNS
- Phone Number: 00393382131017
- Email: contia@unime.it
Study Locations
-
-
-
Messina, Italy, 98125
- Recruiting
- Department of Neurosurgery, University of Messina
-
Contact:
- Alfredo Conti, MD, PhD, FEBNS
- Phone Number: 00393382131017
- Email: contia@unime.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Traumatic brain injuries
- Moderate trauma
- Glasgow Coma Score 9-13
- Loss of consciousness lasting >1 min
- post-traumatic amnesia >20 minutes
- CT scan Marshall Scale class II-VI.
Exclusion Criteria:
- Spinal cord injuries
- Pre-existing neurological disorders affecting the brain and/or the spinal cord
- Severe hypertension
- Diabetes, and chronic renal disease
- Remarkable chronic cerebravasculopathy of the CT
- Severe cognitive deficit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:
|
|
Experimental: Study Group
Standard treatment plus specific treatment.
The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e.
diabetes, arterial hypertension).
|
Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive outcome assessed Mini Mental State Examination (MMSE)
Time Frame: All patients will undergo neurological and neuropsychological evaluations at baseline (T0), after 30 days (T30) and 6 months (T180)
|
Impairment of cognitive abilities will be evaluated by the Mini Mental State Examination (MMSE) (Folstein et al., 1975) adjusted for educational level and age.
This is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.
It is commonly used in medicine and allied health to screen for dementia.
It is also used to estimate the severity and progression of cognitive impairment and to follow the course of cognitive changes in an individual over time that is within the scope of this research.
The threshold value for normal performance is set to 24 points.
The outcome measure will be represented by the absolute score and by the change between the score recorded after 180 days and the baseline value
|
All patients will undergo neurological and neuropsychological evaluations at baseline (T0), after 30 days (T30) and 6 months (T180)
|
Cognitive outcome assessed by the Brief Neuropsychological Cognitive Examination (BNCE)
Time Frame: All patients will undergo neurological and neuropsychological evaluations at baseline (T0), after 30 days (T30) and 6 months (T180)
|
Brief Neuropsychological Cognitive Examination (BNCE) (Ball et al., 2009).
This consists in 10 subtests composed of easily administered tasks, none requiring more than minimal reading skills.Total score indicating overall severity of impairment (expressed in percentage), subtest scores, and two aggregate scores for the simple and complex subtests are provided as percentage of the maximum score.
The outcome measure will be represented by the absolute score and by the difference between the score recorded after 180 days and the baseline value
|
All patients will undergo neurological and neuropsychological evaluations at baseline (T0), after 30 days (T30) and 6 months (T180)
|
Depression outcome assessed by Beck Depression Inventory
Time Frame: Outcome measure will be assessed at 180 days (T180) after trauma
|
Depression will be assessed by the Beck inventory depression scale.This is a 21-question multiple-choice (scored 0-3 each) self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression. Scores will be categorized as follows: 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression Depression score will be assessed at 180 days (T180) after trauma |
Outcome measure will be assessed at 180 days (T180) after trauma
|
Assessment of Independence by Barthel Index
Time Frame: Outcome measure will be assessed at 180 days (T180) after trauma
|
Independence in activities of daily living and self-care will be assessed by the Barthel Index.
This is an ordinal scale used to measure performance in activities of daily living (ADL).
Each performance item is rated on this scale with a given number of points assigned to each level or ranking.
Each domain is scored in one-point increments with a full score of 20 indicating functional independence.
Independence will be assessed at 180 days (T180) after trauma
|
Outcome measure will be assessed at 180 days (T180) after trauma
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLIA13_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
First Affiliated Hospital Xi'an Jiaotong UniversityXijing Hospital; Second Affiliated Hospital of Wenzhou Medical University; Central... and other collaboratorsRecruitingMTBI - Mild Traumatic Brain Injury | Moderate Traumatic Brain InjuryChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityHealth Science Center of Xi'an Jiaotong University; The Second Affiliated Hospital...RecruitingMTBI - Mild Traumatic Brain InjuryChina
Clinical Trials on Co-ultraPEALut (Glialia)
-
University Of PerugiaFederico II University; Azienda Ospedaliero-Universitaria Careggi; Humanitas... and other collaboratorsCompletedCovid19 | Anosmia | Treatment Compliance | Parosmia | HyposmiaItaly
-
Haukeland University HospitalCompleted
-
Boston Medical CenterNot yet recruitingSubstance Use Disorders | Mental Health IssueUnited States
-
Johns Hopkins UniversityNational Institute of Nursing Research (NINR)Active, not recruitingQuality of Life | Multimorbidity | Symptom ManagementUnited States
-
Federal University of Minas GeraisCompletedAttention Deficit and Disruptive Behavior Disorders | Motor Skills DisordersBrazil
-
Memorial Sloan Kettering Cancer CenterTerminated
-
PXL University CollegeRecruitingExercise | Older Adults | Mobile ApplicationBelgium
-
IpasTerminatedAbortion, Induced | Abortion, IncompleteMexico, South Africa
-
Children's Hospital of PhiladelphiaChildren's Anesthesiology Associates, Ltd.CompletedScoliosis | Spinal FusionUnited States
-
University of RochesterRecruiting